CPAP Therapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Continuous Positive Airway Pressure (CPAP) therapy is the established gold-standard treatment for moderate-to-severe obstructive sleep apnoea (OSA) — a chronic condition characterised by repeated partial or complete collapse of the upper airway during sleep, causing recurrent oxygen desaturations, sleep fragmentation, and daytime sleepiness. CPAP works by delivering a continuous flow of pressurised air through a mask worn over the nose or nose and mouth during sleep, creating a pneumatic splint that maintains upper airway patency throughout the respiratory cycle, preventing the airway collapse that causes apnoeas and hypopnoeas.

The CPAP device consists of a flow generator (the CPAP machine), connecting tubing, and a patient interface (mask). Fixed-pressure CPAP delivers a constant prescribed pressure; auto-titrating CPAP (APAP) uses algorithms to continuously adjust pressure within a preset range in response to detected airway events, providing the minimum effective pressure needed. Bi-level PAP (BiPAP or BPAP) delivers separate higher inspiratory pressure (IPAP) and lower expiratory pressure (EPAP) and is used for patients with OSA plus respiratory failure, elevated CO2, or who cannot tolerate the expiratory pressure of CPAP. The prescribed pressure level is determined through in-laboratory polysomnography (PSG) pressure titration or increasingly through home APAP titration and analysis of downloaded CPAP usage data.

OSA affects approximately 1 billion people worldwide, with approximately 30% of adults in developed countries having some degree of OSA and 10-17% having moderate-to-severe disease (AHI ≥15 events/hour). Despite its extremely high prevalence, OSA remains underdiagnosed. CPAP therapy eliminates apnoeas and hypopnoeas, normalises oxygen saturation throughout sleep, restores normal sleep architecture, eliminates snoring, and relieves daytime sleepiness — producing profound improvements in quality of life, cognitive function, cardiovascular risk, and safety from OSA-related driving accidents.

CPAP is the first-line treatment for moderate-to-severe obstructive sleep apnoea (AHI ≥15 events/hour, or AHI ≥5 with significant symptoms or comorbidities). It is also used for mild OSA (AHI 5-14.9) in patients with significant daytime symptoms, cardiovascular disease, or occupational driving risk. Beyond OSA itself, CPAP addresses the cascade of health consequences caused by untreated OSA: uncontrolled hypertension (OSA is the most common secondary cause of hypertension), recurrent atrial fibrillation, nocturnal cardiac arrhythmias, non-restorative sleep, excessive daytime sleepiness causing occupational and driving impairment, and cognitive dysfunction including memory, attention, and executive function deficits.

CPAP is also used in obesity hypoventilation syndrome (OHS — Pickwickian syndrome) alongside weight loss management, in Central Sleep Apnoea (CSA) in selected patients (though adaptive servo-ventilation is usually preferred), and as an adjunct during perioperative care for OSA patients undergoing surgery where sedatives and anaesthetics potentiate upper airway collapse. Evidence supports CPAP treatment in pregnant women with OSA given the association between untreated OSA and gestational hypertension and pre-eclampsia.

CPAP is indicated for patients with polysomnography (PSG)-confirmed or home sleep apnoea test (HSAT)-confirmed moderate-to-severe OSA (AHI ≥15). For mild OSA, clinical symptom assessment and comorbidity profile guide the treatment decision. Ideal candidates are patients with significant daytime sleepiness (Epworth Sleepiness Scale ≥10), documented moderate-to-severe OSA, motivation to use CPAP, and willingness to work through an adjustment period with the mask and device. Patients with cardiovascular comorbidities (hypertension, heart failure, atrial fibrillation) have particularly strong indication for CPAP given cardiovascular benefits.

There are few absolute contraindications to CPAP; relative challenges include claustrophobia, mouth breathing (requiring full-face or chin strap), nasal congestion (requiring heated humidifier and nasal decongestant treatment), significant central apnoea (which CPAP may worsen), and bullous lung disease (theoretical risk of barotrauma with high pressures). Central sleep apnoea or treatment-emergent central sleep apnoea (Complex Sleep Apnoea Syndrome) may require different modalities. Patients who fail standard CPAP despite optimisation of mask, humidification, and pressure settings may be candidates for mandibular advancement device (MAD), upper airway stimulation therapy (Inspire), or surgical treatment for OSA.

Fixed-pressure CPAP (prescribed after PSG pressure titration) delivers a constant pressure optimal for the individual patient. APAP (Auto-PAP) adjusts pressure automatically within a set range, is preferred for patients whose pressure requirements vary (different sleep positions, alcohol use, positional OSA), and enables therapy initiation without a formal in-laboratory titration study. BiPAP is used for patients with comorbid respiratory failure, very high pressure requirements (>15 cm H2O), or significant expiratory pressure intolerance causing arousal.

Mask interface selection is critical for CPAP success. Nasal masks (covering only the nose) are most commonly used and preferred by most patients. Nasal pillow masks (sealing at the nares) provide a minimally intrusive option for patients who feel claustrophobic with full masks. Full-face masks (covering nose and mouth) are required for consistent mouth breathers. Heated humidification (integral to most modern CPAP devices) addresses the mucosal dryness and congestion that commonly cause CPAP abandonment. Telemonitoring through device wireless connectivity enables remote review of adherence data (usage hours, AHI residual, leak rate) by the clinical team to identify problems early and optimise therapy. Auto-titrating CPAP (APAP) devices dynamically adjust pressure breath-by-breath within a pre-set range (typically 4–20 cmH2O) in response to detected flow limitation, snoring, and apnoea events, eliminating the need for manual pressure titration in most patients and improving comfort during positional or REM-related pressure requirement variation throughout the night.

The benefits of CPAP therapy in adherent users are well-established across multiple domains. Daytime sleepiness (measured by Epworth Sleepiness Scale) improves by an average of 2-5 points with CPAP; objective cognitive performance measures (sustained attention, working memory, executive function) improve significantly within weeks. Quality of life instruments (SF-36, Functional Outcomes of Sleep Questionnaire — FOSQ) show clinically meaningful improvement with CPAP adherence. Snoring is eliminated in virtually all patients — a major quality-of-life benefit for bed partners.

Cardiovascular benefits include significant reductions in nocturnal and daytime blood pressure (meta-analyses show systolic BP reduction of 2-4 mmHg — clinically significant given a 5 mmHg reduction reduces stroke risk by ~25%), reduced atrial fibrillation recurrence after cardioversion, and improved nocturnal cardiac arrhythmia burden. Motor vehicle crash risk (2-7 times higher in untreated OSA patients) is reduced to near-normal levels with effective CPAP use. Endocrine and metabolic effects include improved insulin sensitivity and modest glycaemic improvement in patients with comorbid type 2 diabetes. For patients with OSA and heart failure, CPAP significantly improves LVEF (left ventricular ejection fraction) and functional capacity.

CPAP is a non-invasive therapy with a very favourable safety profile — there are no serious medical risks from the therapy itself. Common adverse effects are mask-related: pressure sores and skin breakdown over bony prominences (nasal bridge, cheek), air leaks causing dryness, eye irritation, and aerophagia (swallowing air) causing bloating and flatulence. These issues are managed through mask refitting, skin care barriers, and pressure adjustment. Nasal congestion, rhinorrhoea, and mucosal dryness are minimised with heated humidification and nasal steroids if required.

Claustrophobia and mask discomfort are the primary reasons for CPAP non-adherence — approximately 30-50% of patients abandon CPAP by 1 year. Desensitisation programmes, trial of different mask types, and supportive behavioural counselling significantly improve adherence. Treatment-emergent central sleep apnoea (TECSA) — the development of central apnoeas after OSA is resolved by CPAP — occurs in approximately 5-8% of patients and may require transition to adaptive servo-ventilation (ASV). In the rare patient with severe bullous COPD or high-risk lung disease, barotrauma from high CPAP pressures is a theoretical concern, though extremely rare in practice.

CPAP therapy initiation requires structured follow-up to optimise adherence and efficacy. Clinical review at 2-4 weeks post-initiation assesses subjective symptom response, downloads and reviews device usage data (target: ≥4 hours use per night, ≥5 nights per week), identifies and addresses mask fit issues, adjusts humidification settings, and provides motivational support. Annual review includes comprehensive assessment of adherence, residual symptom burden, blood pressure control, and comorbidity management. In the UK, NICE recommends CPAP with ongoing clinical support.

Patients must clean mask components (cushion, frame, headgear, tubing) regularly according to manufacturer recommendations to prevent bacterial contamination and maintain mask seal. CPAP machine filters require replacement every 1-3 months. Most CPAP devices have a lifespan of 5-7 years. Modern CPAP devices transmit nightly usage and event data wirelessly to clinical portals, enabling proactive remote monitoring and early intervention when adherence falls or residual AHI increases. Driving licence implications apply in many countries — patients with OSA have legal obligations regarding driving fitness, which CPAP compliance can satisfy in most licensing frameworks.

CPAP devices cost USD 500-3,000 depending on features (fixed vs APAP, integrated humidification, telemonitoring), with consumables (masks, cushions, filters, tubing) adding USD 200-500 annually. In the UK, CPAP is provided free on the NHS to patients meeting diagnostic criteria. In Australia, CPAP is subsidised under the Continuous Positive Airway Pressure (CPAP) Benefit Scheme. In the USA, CPAP is covered by Medicare for confirmed severe OSA with documented usage compliance, and by most private insurers; out-of-pocket costs vary by plan.

In India and Southeast Asia, CPAP devices from leading brands (ResMed, Philips Respironics) are available at significantly lower cost (USD 200-800) than in Western markets. Sleep medicine consultations, diagnostic polysomnography, and CPAP pressure titration are available at accredited hospitals in India, Thailand, and Singapore at 40-70% below Western pricing. For international patients with undiagnosed or untreated OSA, diagnostic workup and CPAP initiation during a medical tourism visit to an Indian or Thai accredited sleep centre provides comprehensive management at significant cost savings.

Mandibular advancement devices (MADs) — custom-fitted dental appliances that advance the lower jaw during sleep to increase upper airway space — are a well-evidenced alternative for mild-to-moderate OSA or for patients who cannot tolerate CPAP. Meta-analyses show MADs achieve a smaller AHI reduction than CPAP but with better adherence, resulting in comparable real-world effectiveness in many patients. Upper airway stimulation therapy (Inspire hypoglossal nerve stimulator) is a surgically implanted device that activates the genioglossus muscle during each inspiration, preventing tongue base collapse — approved for moderate-to-severe OSA in CPAP-intolerant patients.

Surgical upper airway procedures — including uvulopalatopharyngoplasty (UPPP), tonsillectomy for OSA, tongue base reduction, and maxillomandibular advancement (MMA) — achieve significant AHI reductions in selected patients but rarely achieve complete OSA elimination, and are generally considered when CPAP and MAD have failed. Weight loss (bariatric surgery or intensive lifestyle intervention) is the most effective long-term strategy for OSA in obese patients, with weight loss of 10-15% of body weight reducing AHI by 30-40%. Positional therapy (vibrotactile devices preventing supine sleep) is effective for positional OSA (where AHI is ≥2 times higher in the supine versus non-supine position).